ASCO 2022
More data needed: Are the results clinical meaningful? How can SG fit in the therapy algorithm?
TROPiCS-02
ASCO 2022
More data needed: Are the results clinical meaningful?…
MAINTAIN
ASCO 2022
CDK4/6i switch: who benefits from switching the CDK4/6…
PALOMA-2
ASCO 2022
What are the cosenquences of the new OS data for CDK4/6…
Destiny-Breast04
ASCO 2022
Paradigm shift in breast cancer: Where do we use the…
ASCO 2022
Transatlantic differences in ADC side effects…
Tropics02; Destiny-Breast04
ASCO 2022
Patients perspectives: ADCs - how do manage the new,…
Destiny-Breast04
ASCO 2022
Determining HER2 receptor expression: How do we target…
TROPiCS-02
ASCO 2022
What clincial value has statistical signifcance? How…
MAINTAIN
ASCO 2022
How to determine progress of disease? How to proceed…
Destiny-Breast04; U31402-A-J101; PALOMA-2; MAINTAIN
ASCO 2022
ADCs & CDK4/6i - paradigm shifts and therapy switches…
ASTER
ASCO 2022
Endocrine therapy alone is important in treatment of…
Tropics02
ASCO 2022
Good therapeutic option in HR+ HER2- mBC after failure…
NeoSTAR
ASCO 2022
Sacituzumab govitecan improves PCr in patients with…
Destiny-Breast04
ASCO 2022
New standard of care for HR+/Her2low patients
Destiny-Breast 04; Tropics-02
ASCO 2022
Impressive and practice changing data of ADCs mark the…
DESTINY-Breast04; TROPiCS-02
ASCO 2022
Breakthrough news with antibody drug conjugate
coopERA BC
ASCO 2022
Combi SERD + Palbo reduces proliferation better than…
Destiny-Breast04
ASCO 2022
Practice changing data
Destiny-Breast04
ASCO 2022
T-DxD should be the new SoC for Her2low MBC patients
Destiny-Breast04
ASCO 2022
New SoC for large subpopulation of breast cancer…
Destiny-Breast04
ASCO 2022
Gamechanger in breast cancer
ASCO 2022
Patritumab Deruxtecan: HER3-targeted ADC in HER3…
NRG-BR002
ASCO 2022
No effect for local treatment of metastasis
Tropics02; Destiny-Breast04
ASCO 2022
Fascinating data of ADCs in breast cancer at ASCO22
PALOMA-2; MAINTAIN
ASCO 2022
No changes in clinical practice after new CDK4/6i-data
MAINTAIN
ASCO 2022
Benefit of CDK4/6 Switch after Progression
Tropics02
ASCO 2022
SG is a new therapy option for HR+/HER2- MBC patients
TROPICS-02; Destiny-Breast04
ASCO 2022
Exciting advances across a wide subset of breast…
NRG-BR002
ASCO 2022
Oligometastasis: no advantage of additional…
MAINTAIN
ASCO 2022
Additional administration of ribociclib improves PFS…
TROPiCS-02
ASCO 2022
Smart chemotherapy improves PFS
Destiny-Breast04
ASCO 2022
Revolution in the field of HR+ disease
TROPiCS-02
ASCO 2022
SG may be a good option for pre-treated HR+/Her2- pts
Destiny-Breast04, Destiny-Breast03, TROPiCS-2, PALOMA-2, MAINTAIN, NRG-BR002
ASCO 2022
My ASCO22 highlights in metastatic breast cancer
TROPiCS-02
ASCO 2022
ADC: future therapeutic option in advanced HR+/HER2 BC
MAINTAIN
ASCO 2022
First evidence on benefit of CDK4/6 inhibitors beyond…
Destiny-Breast04
ASCO 2022
Exciting and practice changing news for HR+/Her2low MBC…
NRG-BR002
ASCO 2022
Discontiunation of trial is disappointing despite…
PALOMA-2
ASCO 2022
Disappoiting final OS data and its implications for our…
PALOMA-2
ASCO 2022
Palbociclib - Overall survival data
DESTINY-Breast04; TROPiCS-02
ASCO 2022
New agents for the clincial practice
PALOMA-2
ASCO 2022
Possible explanations of the negative study
FAKTION
ASCO 2022
Improvment of PFS & OS with activated alteration…
FAKTION
ASCO 2022
Option for overcoming endocrine resistance?
BioItaLEE
ASCO 2022
Combination of ctDNA and TKa assesment may improve…
DESTINY-Breast04; TROPiCS-02
ASCO 2022
ADCs en cáncer de mama con receptores hormonales…
TROPiCS-02
ASCO 2022
Il sacituzumab govitecan migliora il PFS nei tumori…
Destiny-Breast04
ASCO 2022
Novità entusiasmanti e practice changing per le…
BioItaLEE
ASCO 2022
La valutazione combinata di ctDNA e TKa può aiutare a…
MAINTAIN
ASCO 2022
Pierwsze dane nt. skuteczności inhibitorów CDK4/6 po…
Destiny-Breast04
ASCO 2022
Una rivoluzione per il tumore mammario…
Destiny-Breast 04; Tropics-02
ASCO 2022
Les nouvelles données impressionnantes des ADC à l’ASCO…
Destiny-Breast 04; Tropics-02
ASCO 2022
I nuovi impressionanti risultati degli ADC a l’ASCO…
Destiny-Breast04
ASCO 2022
Nowy standard dla znaczącej subopulacji chorych na raka…
Tropics02
ASCO 2022
SG come nuova opzione di cura per le pazienti con…
PALOMA-2; MAINTAIN
ASCO 2022
PALOMA2 e MAINTAIN: cosa cambia nella pratica clinica?
Destiny-Breast04, Tropics-02
ASCO22
Noutăți inovatoare cu conjugatul de medicamente cu…
LUMINA
ASCO 2022
Adding towards deescalation in luminal A EBC by…
ASTRRA
ASCO 2022
Ovarian function suppression - it is here to stay!
Aster 70s
ASCO 2022
CT benefit for elderly patients, if they are able to…
KEYNOTE-522; NeoSTAR
ASCO 2022
Neoadjuvant Pembro decreased RCB. SG - first promising…
ABCSG-18
ASCO 2022
Long term overall survival benefit of Denosumab in…
coopERA BC
ASCO 2022
Combi SERD + Palbo redzuert proliferation better than…
ADAPT
ASCO 2022
High concordance of local, central IHC and RT-PCR for…
iSPY-2, Keynote-522, ASTER-70s, ASTRRA, ABCSG-18
ASCO 2022
My ASCO22 highlights in early breast cancer
CHRYSALIS-2; CHRYSALIS
ASCO 2022
Molecular landscape - Part 2
Lung-MAP
ASCO 2022
Immunotherapy - Part 2
CheckMate 227; CheckMate 9LA; FDA pooled
ASCO 2022
Immunotherapy - Part 1
KRYSTAL-1
ASCO 2022
Molecular landscape - Part 1
ASCO 2022
CLN-081 is a promising new agent for EGFR exon 20…
CHRYSALIS
ASCO 2022
New treatment options for METexon 14 skipping:…
CHRYSALIS-2; CHRYSALIS
ASCO 2022
New components and therapies for advanced NSCLC
COSMIC-021
ASCO 2022
COSMIC-021: Not practice-changing, but interesting…
FDA pooled analysis
ASCO 2022
PD-L1 over 50%: Chemo-IO or IO?
KRYSTAL-1
ASCO 2022
Promising results for pre-treated patients with…
Lung-MAP; KRYSTAL-1
ASCO 2022
Options after progression to chemo/IO and for KRASG12C…
CodeBreaK100
ASCO 2022
Multiple aquired resistance mutations may drive disease…
ASCO 2022
CLN-081 for patients with metastatic NSCLC and an…
KRYSTAL-1
ASCO 2022
KRASG12C mutation: Adagrasib is comparabale to…
KRYSTAL-1
ASCO 2022
Is adagrasib an alternative to sotorasib?
FDA pooled analysis
ASCO 2022
Strategies for PD-L1 > 50%
KRYSTAL-1
ASCO 2022
In the second line: Options for Immunotherapy…
CHRYSALIS
ASCO 2022
Amivantamab as a future option for METex14 patients?
FDA pooled
ASCO 2022
Role of IO and chemo-IO in patients with PD-L1 > 50%
CHRYSALIS-2
ASCO 2022
A chemo-free option in patients with EGFR-mutation
CHRYSALIS
ASCO 2022
Bispecific Antibodies - the cMET field is moving
CHRYSALIS
ASCO 2022
New option in patients harboring METex14 mutation
KRYSTAL-1
ASCO 2022
Veelbelovende resultaten voor voorbehandelde patienten…
COSMIC-021
ASCO 2022
COSMIC-021: Nicht praxisverändernd, aber interessante…
ASCO 2022
Bispezifische Antikörper - Neues von CHRYSALIS
KRYSTAL-1; Lung-MAP
ASCO 2022
Segunda Linea: opciones tras resistencia a…
CHRYSALIS-2; CHRYSALIS
ASCO 2022
Nuevas terapias para el CPCNP avanzado
FDA pooled
ASCO 2022
Die Rolle von IO und Chemo-IO bei Patienten mit PD-L1 >…
ASCO 2022
Was tun nach Versagen einer Chemoimmun-Therapie?
CHRYSALIS
ASCO 2022
Une nouvelle option, l’amivantamab, en situation de…
CHRYSALIS
ASCO 2022
Nieuwe behandelopties voor METexon 14 skipping:…
ASCO 2022
CLN-081 voor patienten met gemetastaseerd NSCLC en een…
ASCO 2022
PD-L1 über 50 % - was tun?
KRYSTAL-1
ASCO 2022
L’adagrasib, inhibiteur de la mutation KRASG12C: une…
NADIM II; CheckMate 816
ASCO 2022
Neoadjuvant and adjuvant therapy - Part 1
NADIM II; CheckMate 816
ASCO 2022
Neoadjuvant and adjuvant therapy - Part 2
NADIM II
ASCO 2022
A new option in neoadjuvant chemoimmunotherapy
NADIM-II
ASCO 2022
NADIM-II strengthens the findings from CheckMate-816
NADIM II
ASCO 2022
Perspectives on multimodality
CheckMate-816
ASCO 2022
CheckMate-816: Neoadjuvant therapy
KEYNOTE-799
ASCO 2022
New treatment approaches in Stage III
KEYNOTE-799
ASCO 2022
Neue Ansätze im Stadium III
NADIM II
ASCO 2022
Chimiothérapie néoadjuvante des stades III , vers un…
SKYSCRAPER-02
ASCO 2022
SKYSCRAPER-02: Subgroups could be important
ASCO 2022
Immuncheckpoint-inhibitor therapy
SKYSCRAPER-02
ASCO 2022
SCLC-Update: No benefit with Tiragolumab/Chemo-IO is…
SKYSCRAPER-02
ASCO 2022
No benefit for tiragolumab / novel anti-PD-1 mAB…
SKYSCRAPER-02
ASCO 2022
Le Tiragolumab n’apporte pas de bénéfice à la…
Propel; MAGNITUDE; BRCAAWAY
ASCO 2022
PARP inhibitors in mCRPC: Do we need more genetic…
TheraP; VISION
ASCO 2022
mCRPC: LuPSMA - new treatment option in mCRPC
ENZAMET; ARASENS
ASCO 2022
mHSPC: Transatlantic differences in genetic testing &…
ARAMIS
ASCO 2022
Frequent imaging for early detection of metastases in…
TheraP
ASCO 2022
LuPSMA & cabazitaxel are better than SoC alone
ARASEC
ASCO 2022
Value of triple-therapy - complimentary study to…
ASCO 2022
Phase 1 study on combining LuPSMA treatment with…
CHART
ASCO 2022
SHR3680 - do we need a new androgen receptor inhibitor
VISION
ASCO 2022
Further updates from the VISION trial
TheraP
ASCO 2022
TheraP shows no difference in overall survival between…
TheraP
ASCO 2022
3 year overall survival of TheraP study
VISION
ASCO 2022
SUV mean at PET images as a prognostic tool for PSMA…
Vision
ASCO 2022
SUVmean is highly predictive of better PFS and OS
ENZAMET
ASCO 2022
The efficacy of doublets in mHSPC
The highlights in GU cancers of ASCO22
ASCO 2022
The highlights in GU cancers of ASCO22
ASCO 2022
PFS good surrogate endpoint for overall survival
BRCAAWAY
ASCO 2022
Arbiraterone + Olaparib: Is it synergistic?
ASCO 2022
Ongoing trial invetiagting the impact of…
ASCO 2022
Surrogate endpoints in mHSPC
TheraP
ASCO 2022
Lu-PSMA in the third line
VISION
ASCO 2022
Lu-PSMA effective regardless of prior or concomitant…
ENZAMET
ASCO 2022
No big scoop, but encouraging results
ASCO 2022
GGT impacts PCa patients care
ENZAMET
ASCO 2022
ADT alone is no longer standard of care
ASCO 2022
Pas de nouvelles sensationnelles mais des données…
TheraP
ASCO 2022
Treårs överlevnadsresultat i TheraP studien.
ASCO 2022
Lo mas destacado en tumores GU en ASCO 2022
ASCO 2022
Kombination av 177-LU-PSMA-617 och pembrolizumab I Fas…
VISION
ASCO 2022
Kvantifiering av PMSA PET upptaget som prognostisk…
ASCO 2022
Tidigare endpoints I mHSPC studier
CheckMate9ER
ASCO 2022
What are the consequences for future trial design?
CLEAR Study; KEYNOTE-426; CheckMate (CM) 214; CheckMate 9ER
ASCO 2022
Combination Therapy is State of the Art in Metastatic…
CheckMate214
ASCO 2022
The relevance of quality of life in kidney cancer!
EVEREST
ASCO 2022
EVEREST: Inisghts from the negative trial
ASCO 2022
PSMA-PET may improve imaging of clear cell RCC
The highlights in GU cancers of ASCO22
ASCO 2022
The highlights in GU cancers of ASCO22
CheckMate 9ER
ASCO 2022
Depth of remission in firstline
LITESPARK-004
ASCO 2022
Clear evidence for durable benefit for patients with…
EVEREST
ASCO 2022
Should we be looking at Everolimus in the future?
LITESPARK-004
ASCO 2022
Belzutifann shows good tumor activity in renal cancer
CheckMate 9ER; CheckMate 214
ASCO 2022
QoL & DepOR correlate with clinical outcomes - reminder…
KEYNOTE-426
ASCO 2022
Combi Axi + Pembro also successful with good risk…
ASCO 2022
Importance of health related quality of life
EVEREST
ASCO 2022
Should Everolimus be revisited for high-risk patients?
ASCO 2022
Lo mas destacado en tumores GU en ASCO 2022
ASCO 2022
Pas de nouvelles sensationnelles mais des données…
AURA; SAKK 06/17; JAVELIN
ASCO 2022
The role of systemic treatment in the pre-operative…
EV-103; RC-48
ASCO 2022
ADCs: do we enter a new era of therapy for urothelial…
COSMIC-021
ASCO 2022
New data on TKi utilization in bladder cancer
ASCO 2022
Maintenance concepts
ENZAMET
ASCO 2022
No big scoop, but encouraging results
SAKK 06/17
ASCO 2022
Perioperative immuno-chemotherapy in MIBC
ASCO 2022
BCG failure
QUILT 3.032; SWOG S1314
ASCO 2022
My highlights in localized urothelial cancer
COSMIC-021; ATLANTIS
ASCO 2022
The end of of VEGF-targeted therapy in urothelial…
ASCO 2022
ADCs: News from ASCO 2022
The highlights in GU cancers of ASCO22
ASCO 2022
The highlights in GU cancers of ASCO22
ATLANTIS; MAIN_CAV
ASCO 2022
My highlights of metastasized urothelial cancer
CREST cohort B
ASCO 2022
Investigating sasanlimab in BCG-unresponsive NMIBC
EV-301; RC48-ADC
ASCO 2022
Exciting future for ADCs
ASCO 2022
Σημαντικά μηνύματα για τον ουροθηλιακό καρκίνο από το…
ASCO 2022
Lo mas destacado en tumores GU en ASCO 2022
ASCO 2022
Few testicular tumors after 5 years
ASCO 2022
News from Sarcoma
ASCO22
Opportunities & challenges of cancer genetics
ASCO 2022
Radiotherapy as a new standard for cisplatin ineligible…
ASCO 2022
Systemic therapy
ASCO 2022
Precision oncology - NTRK worth to search the patients
Für den erfolgreichen Abschluss der Fortbildungsmodule ist die korrekte (mind. 70%) Beantwortung der Lernerfolgskontrolle für das jeweilige Modul verpflichtend.
Jetzt gleich den Fragebogen ausfüllen!